Ustekinumab (Stelara, Janssen), which was recently approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe Crohn's disease, is an antibody directed against the p40 subunit shared by IL12 and 23May 22, 19First to market was Johnson &Consistently, neutralizing antibodies against IL12/IL23 p40 and IL23 p19 have been successfully used in clinical trials for therapy of Crohn´s disease and pilot studies in
Il 12 Il 23 And Il 17 In Ibd Immunobiology And Therapeutic Targeting Nature Reviews Gastroenterology Hepatology